1. Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma
- Author
-
BA Miranda Youssef, Leslie H. Blumgart, Edmund C. Burke, Mithat Gonen, David S. Klimstra, William R. Jarnagin, Ronald P. DeMatteo, Yuman Fong, and BS Jessica Bodniewicz
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Preoperative care ,Disease-Free Survival ,Metastasis ,Cholangiocarcinoma ,Preoperative Care ,medicine ,Hepatectomy ,Humans ,Prospective Studies ,Stage (cooking) ,Survival rate ,Aged ,Neoplasm Staging ,Probability ,Aged, 80 and over ,business.industry ,Scientific Papers of the American Surgical Association ,Klatskin's tumor ,Perioperative ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Surgery ,Survival Rate ,Klatskin tumor ,Bile Ducts, Intrahepatic ,Treatment Outcome ,Bile Duct Neoplasms ,Female ,Radiology ,business ,Follow-Up Studies - Abstract
Cholangiocarcinoma is a rare disease, accounting for less than 2% of all human malignancies. 1 Although the entire biliary tree is potentially at risk, tumors involving the biliary confluence or the right or left hepatic ducts (hilar cholangiocarcinoma) are most common and account for 40% to 60% of all cases. 2–6 Meaningful clinical experience in managing hilar cholangiocarcinomas has been limited to a few referral centers because of the infrequency with which they are encountered. Although resection has long been recognized as the most effective therapy for hilar cholangiocarcinoma, 7 the importance of partial hepatectomy and the willingness of surgeons to use it routinely are relatively recent developments. 2,8–10 Many clinical series extend over a prolonged period, often greater than 20 years. 4,5,9,11,12 As a result, these reports lack a uniform approach to diagnosis, assessment of disease extent, and resection, and the results are therefore difficult to interpret. Further, most studies originate from surgical departments and tend to focus on surgical findings and results and often do not provide a full accounting of all patients seen. Long-term survival in patients with hilar cholangiocarcinoma depends critically on complete tumor resection. 2,10 In the absence of widespread disease, the likelihood of achieving a complete resection requires examination of all factors related to local tumor extent, which increasingly has become possible with noninvasive imaging studies. 13,14 Tumor location and extent within the biliary tree, as provided by the Bismuth-Corlette classification system, 15,16 is only one component. Additional factors that must be addressed relate to radial tumor growth and its impact on adjacent structures, specifically portal venous involvement and consequent hepatic lobar atrophy. Both the modified Bismuth-Corlette and the American Joint Committee on Cancer 17 staging systems fail to account for all of these local, tumor-related factors, which frequently influence therapy. We have shown previously that a preoperative staging system that accounts fully for local tumor-related factors accurately predicts resectability and correlates with survival. 2 The present study represents an analysis of all patients with hilar cholangiocarcinoma seen and treated at a single institution during a 9-year period. The organizational structure of the hepatobiliary program at Memorial Sloan-Kettering Cancer Center (MSKCC) allows a multidisciplinary review of all patients, regardless of disease stage. Thus, a full accounting of all patients, including those with unresectable tumors, is possible. The relatively short time interval ensures homogeneity with respect to disease assessment and surgical approach. This study also proposes a preoperative staging system, based on imaging data and modified from a previous report, 2 that stratifies patients into treatment groups with predictable resectability rates and survival.
- Published
- 2001
- Full Text
- View/download PDF